B7 homolog 6 promotes the progression of cervical cancer.
B7 homolog 6
HeLa cells
apoptosis
biological function
cell cycle
cervical cancer
Journal
Experimental and therapeutic medicine
ISSN: 1792-0981
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
15
09
2020
accepted:
12
04
2021
entrez:
31
5
2021
pubmed:
1
6
2021
medline:
1
6
2021
Statut:
ppublish
Résumé
B7 homolog 6 (B7-H6) was recently discovered to act as a co-stimulatory molecule. In particular, the expression of B7-H6 has been found to play an important biological role in several types of tumors. The aim of the present study was to determine the role of B7-H6 in cervical cancer. Immunohistochemistry was used to analyze the expression levels of B7-H6 in cervical precancerous and cancerous tissues. Furthermore, the expression of B7-H6 was knocked down in HeLa cells using short hairpin RNA and the effects of B7-H6 on HeLa cell proliferation, migration and invasion were determined using Cell Counting Kit-8, colony formation, wound healing and Transwell invasion assays, respectively. In addition, flow cytometry was used to analyze the levels of cell apoptosis and the cell cycle distribution. The results of the immunohistochemical staining revealed that the expression levels of B7-H6 were upregulated in cervical lesions. Furthermore, the expression levels of B7-H6 were positively associated with the clinical stage of the cervical lesions. B7-H6 knockdown suppressed the invasive, migratory and proliferative abilities of HeLa cells, and promoted G1 cell cycle arrest and apoptosis. In conclusion, the findings of the present study suggested that B7-H6 may serve as a novel oncogene and may hold promise as a potential therapeutic target for cervical cancer.
Identifiants
pubmed: 34055073
doi: 10.3892/etm.2021.10206
pii: ETM-0-0-10206
pmc: PMC8145428
doi:
Types de publication
Journal Article
Langues
eng
Pagination
774Informations de copyright
Copyright: © Guo et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Oncoimmunology. 2016 Jul 28;5(7):e1116674
pubmed: 27622013
Int J Oncol. 2016 Apr;48(4):1561-70
pubmed: 26891663
Lancet Glob Health. 2021 Feb;9(2):e161-e169
pubmed: 33212031
Curr Treat Options Oncol. 2020 Oct 6;21(12):95
pubmed: 33025260
Clin Chim Acta. 2020 Mar;502:191-198
pubmed: 31904350
Int J Mol Sci. 2019 Jan 03;20(1):
pubmed: 30609841
Biopolymers. 2016 Sep;106(5):658-72
pubmed: 27216712
Cancer Cell Int. 2018 Sep 4;18:126
pubmed: 30186042
J Oral Pathol Med. 2017 Oct;46(9):766-772
pubmed: 28437013
Oncotarget. 2017 Jun 6;8(23):37435-37447
pubmed: 28415577
Sci Rep. 2019 Dec 2;9(1):18122
pubmed: 31792298
Mol Cancer Ther. 2017 Jul;16(7):1203-1211
pubmed: 28679835
J Natl Compr Canc Netw. 2020 Jun;18(6):660-666
pubmed: 32502976
J Biol Chem. 2015 Dec 11;290(50):29964-73
pubmed: 26472927
Pathol Oncol Res. 2018 Oct;24(4):717-721
pubmed: 29086181
Blood. 2013 Aug 1;122(5):684-93
pubmed: 23801635
Oncoimmunology. 2015 Jan 22;4(4):e1001224
pubmed: 26137398
Pathol Oncol Res. 2014 Jan;20(1):203-7
pubmed: 24242703
Obstet Gynecol. 2012 Dec;120(6):1465-71
pubmed: 23168774
Front Immunol. 2019 May 07;10:909
pubmed: 31134055
Int Immunopharmacol. 2018 Jun;59:318-327
pubmed: 29679856
Oncol Lett. 2017 Aug;14(2):2405-2409
pubmed: 28789456
Proc Natl Acad Sci U S A. 2011 Apr 12;108(15):6223-8
pubmed: 21444796
Int J Biol Sci. 2020 Jan 1;16(4):568-582
pubmed: 32025206
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Immunol. 2015 Jun 1;194(11):5305-11
pubmed: 25911747
J Exp Med. 2011 Apr 11;208(4):703-14
pubmed: 21422170
Cancer Res. 2014 Jul 1;74(13):3429-40
pubmed: 24780758
Oncoimmunology. 2016 Jul 11;5(8):e1207841
pubmed: 27622076